Chase Pharmaceuticals, which is helmed by ex-Allergan ($AGN) president Doug Ingram, has raised $12 million, according to a filing with the SEC. The startup is working on a therapy that can be used to allow for higher doses of donepezil in treating Alzheimer's patients. The company has been keeping a low profile so far, and its website is largely a placeholder for what's being planned. Ingram was named CEO back in late 2015. Filing